Journal of Nuclear Cardiology

, Volume 10, Issue 1, pp 77–86 | Cite as

Large animal models of congestive heart failure: A critical step in translating basic observations into clinical applications

  • William M. Yarbrough
  • Francis G. Spinale
Topics in Integrated Systems Physiology


Congestive heart failure (CHF) is a clinical syndrome in which pathophysiologic underpinnings include left ventricular (LV) dysfunction, remodeling, and increased neurohormonal activation. Accordingly, large animal constructs must be developed that mimic this disease process in order to define new pharmacologic and surgical treatment strategies. Multiple large animal species have been used for these purposes. For instance, canine coronary artery microembolization has been used to generate ischemia-induced LV dilation and dysfunction. Sheep have been subjected to total acute coronary artery occlusion to evaluate ischemia-induced mitral valve insufficiency. Rapid ventricular pacing has been used in both dogs and pigs to reproduce the characteristics of dilated cardiomyopathy. Each model is associated with advantages and disadvantages. Therefore findings derived from the study of large animal models of LV failure must be carefully evaluated. With proper interpretation, important insights into the pathogenesis of CHF may be realized. Furthermore, these models may be used in conjunction with imaging modalities such as magnetic resonance imaging, single photon emission computed tomography, and positron emission tomography to elucidate the identification of cellular and extracellular alterations associated with LV failure. Thus large animal models of CHF are critical components in the effort to translate basic observations into beneficial clinical applications. (J Nucl Cardiol 2003;10:77-86.)

Key Words

Congestive heart failure large animal model imaging 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Heart Association. 2002 Heart and stroke statistical update. Dallas: American Heart Association; 2001.Google Scholar
  2. 2.
    Hall C. Interaction and modulation of neurohormones on left ventricular remodeling. In: St John Sutton MG, editor. Left ventricular remodeling after acute myocardial infarction. London: Science Press Ltd; 1996. p. 89–99.Google Scholar
  3. 3.
    Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 1993;22(4 Suppl A):72A-84A.PubMedGoogle Scholar
  4. 4.
    Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248–54.PubMedGoogle Scholar
  5. 5.
    Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84–95.PubMedGoogle Scholar
  6. 6.
    Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001;103:2303–9.PubMedGoogle Scholar
  7. 7.
    Pfeffer MA, Braunwald E, Moye LA, et al. on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669–77.PubMedGoogle Scholar
  8. 8.
    Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569–82.PubMedCrossRefGoogle Scholar
  9. 9.
    Anversa P, Olivetti G, Capasso JM. Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 1991;68:7D-16D.PubMedCrossRefGoogle Scholar
  10. 10.
    Weber KT, Pick R, Janicki JS, Gadodia G, Lakier JB. Inadequate collagen tethers in dilated cardiomyopathy. Am Heart J 1988; 116(6 Pt 1):1641–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Sharov VG, Sabbah HN, Shimoyama H, et al. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996;148:141–9.PubMedGoogle Scholar
  12. 12.
    Reimer KA, Jennings RB. The “wavefront phenomenon” of myocardial ischemic cell death, II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633–44.PubMedGoogle Scholar
  13. 13.
    White FC, Roth DM, Bloor CM. The pig as a model for myocardial ischemia and exercise. Lab Anim Sci 1986;36:351–6.PubMedGoogle Scholar
  14. 14.
    Lowe JE, Reimer KA, Jennings RB. Experimental infarct size as a function of the amount of myocardium at risk. Am J Pathol 1978;90:363–79.PubMedGoogle Scholar
  15. 15.
    McDonald KM, D'Aloia A, Parrish T, et al. Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition. J Card Fail 1998;4:203–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Sabbah HN, Stein PD, Kono T, et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol Heart Circ Physiol 1991;260:H1379–84.Google Scholar
  17. 17.
    Mishima T, Tanimura M, Suzuki G, et al. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2000;35:222–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Saavedra WF, Tunin RS, Paolocci N, et al. Reverse remodeling and enhanced adrenergic reserve from passive external support in experimental dilated heart failure. J Am Coll Cardiol 2002;39:2069–76.PubMedCrossRefGoogle Scholar
  19. 19.
    Weaver ME, Pantely GA, Bristow JD, Ladley HD. A quantitative study of the anatomy and distribution of coronary arteries in swine in comparison with other animals and man. Cardiovasc Res 1986;20:907–17.PubMedCrossRefGoogle Scholar
  20. 20.
    St Louis JD, Hughes GC, Kypson AP, et al. An experimental model of chronic myocardial hibernation. Ann Thorac Surg 2000; 69:1351–7.CrossRefGoogle Scholar
  21. 21.
    Haitsma DB, Bac D, Raja N, et al. Minimal impairment of myocardial blood flow responses to exercise in the remodeled left ventricle early after myocardial infarction, despite significant hemodynamic and neurohormonal alterations. Cardiovasc Res 2001;52:417–28.PubMedCrossRefGoogle Scholar
  22. 22.
    Etoh T, Joffs C, Deschamps A, et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 2001;281:H987–94.PubMedGoogle Scholar
  23. 23.
    Mukherjee R, Widener C, Joffs C, et al. Regional LV mechanics following myocardial infarction: effects of matrix metalloproteinase inhibition [abstract]. J Card Fail 2001;7(3 Suppl 2):7.Google Scholar
  24. 24.
    Brinsa TA, Scott AA, Widener CE, et al. Relation between matrix metalloproteinase activity and myocardial infarct expansion: effects of MMP inhibition [abstract]. J Card Fail 2007 7(3 Suppl 2):24.Google Scholar
  25. 25.
    Gorman JH, Gorman RC, Jackson BM, et al. Distortions of the mitral valve in acute ischemic mitral regurgitation. Ann Thorac Surg 1997;64:1026–31.PubMedCrossRefGoogle Scholar
  26. 26.
    Markovitz LJ, Savage EB, Ratcliffe MB, et al. Large animal model of left ventricular aneurysm. Ann Thorac Surg 1989;48:838–45.PubMedCrossRefGoogle Scholar
  27. 27.
    Rademaker MT, Cameron VA, Charles CJ, et al. Neurohormones in an ovine model of compensated postinfarction left ventricular dysfunction. Am J Physiol Heart Circ Physiol 2000;278:H731–40.PubMedGoogle Scholar
  28. 28.
    Llaneras MR, Nance ML, Streicher JT, et al. Large animal model of ischemic mitral regurgitation. Ann Thorac Surg 1994;57:432–9.PubMedGoogle Scholar
  29. 29.
    Bowen FW, Jones SC, Narula N, et al. Restraining acute infarct expansion decreases collagenase activity in borderzone myocardium. Ann Thorac Surg 2001;72:1950–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Anthony SJ, Schaffner W. Q fever pneumonia. Semin Respir Infect 1997;12:2–6.Google Scholar
  31. 31.
    McDonald KM, Francis GS, Carlyle PF, et al. Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog. J Am Coll Cardiol 1992;19:460–7.PubMedGoogle Scholar
  32. 32.
    Eriksson H. Heart failure: a growing public health problem. J Intern Med 1995;237:135–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Wynne J, Braunwald E. In: Braunwald E, editor. Heart disease. Philadelphia: Saunders; 1997. p. 1404–63.Google Scholar
  34. 34.
    Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Whipple GH, Sheffield LT, Woodman EG, Theophilis C, Friedman S. Reversible congestive heart failure due to rapid stimulation of the normal heart. Proc New Engl Cardiovasc Soc 1961-62;20:39- 40.Google Scholar
  36. 36.
    Tanaka R, Spinale FG, Crawford FA, Zile MR. Effect of chronic supraventricular tachycardia on left ventricular function and structure in newborn pigs. J Am Coll Cardiol 1992;20:1650–60.PubMedGoogle Scholar
  37. 37.
    Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy: disparity between recovery of systolic versus diastolic function. Circulation 1991;83:635–44.PubMedGoogle Scholar
  38. 38.
    Ohno M, Cheng CP, Little WC. Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation 1994;89:2241–50.PubMedGoogle Scholar
  39. 39.
    Wilson JR, Douglas P, Hickey WF, et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation 1987;75:857–67.PubMedGoogle Scholar
  40. 40.
    Moe GW, Stopps TP, Angus C, et al. Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure. J Am Coll Cardiol 1989;13:173–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Spinale FG, Tempel GE, Mukherjee R, et al. Cellular and molecular alterations in the beta-adrenergic system with cardiomyopathy induced by tachycardia. Cardiovasc Res 1994;28:1243–50.PubMedCrossRefGoogle Scholar
  42. 42.
    Eble DM, Spinale FG. Contractile and cytoskeletal content, structure, and mRNA levels with tachycardia-induced cardiomyopathy. Am J Physiol 1995;268(6 Pt 2):H2426–39PubMedGoogle Scholar
  43. 43.
    Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580–6.PubMedGoogle Scholar
  44. 44.
    Tanaka R, Fulbright BM, Mukherjee R, et al. The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol 1993;25:1215–33.PubMedCrossRefGoogle Scholar
  45. 45.
    Calderone A, Bouvier M, Li K, et al. Dysfunction of the beta- and alpha-adrenergic systems in a model of congestive heart failure: the pacing overdrive dog. Circ Res 1991;69:332–43.PubMedGoogle Scholar
  46. 46.
    Hobai IA, O'Rourke B. Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. Circulation 2001;103:1577–84.PubMedGoogle Scholar
  47. 47.
    Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558–69.PubMedGoogle Scholar
  48. 48.
    Spinale FG, de Gasparo M, Whitebread S, et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure, I. Effects on left ventricular performance and neurohormonal systems. Circulation 1997;96:2385–96.PubMedGoogle Scholar
  49. 49.
    Spinale FG, Mukherjee R, Iannini JP, et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure, II. Effects on myocyte contractile processes. Circulation 1997;96:2397–406.PubMedGoogle Scholar
  50. 50.
    Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75.PubMedCrossRefGoogle Scholar
  51. 51.
    McCarthy PM, Takagaki M, Ochiai Y, et al. Device-based change in left ventricular shape: a new concept for the treatment of dilated cardiomyopathy. J Thorac Cardiovasc Surg 2001;122:482–90.PubMedCrossRefGoogle Scholar
  52. 52.
    Moe GW, Stopps TP, Howard RJ, Armstrong PW. Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing-induced heart failure. J Lab Clin Med 1988;112:426–32.PubMedGoogle Scholar
  53. 53.
    Monnet E, Orton EC. A canine model of heart failure by intracoronary adriamycin injection: hemodynamic and energetic results. J Card Fail 1999;5:255–64.PubMedCrossRefGoogle Scholar
  54. 54.
    Toyoda Y, Okada M, Kashem MA. A canine model of dilated cardiomyopathy induced by repetitive intracoronary doxorubicin administration. J Thorac Cardiovasc Surg 1998;115:1367–73.PubMedCrossRefGoogle Scholar
  55. 55.
    Carabello BA, Nolan SP, McGuire LB. Assessment of preoperative left ventricular function in patients with mitral regurgitation: value of the end-systolic wall stress-end-systolic volume ratio. Circulation 1981;64:1212–7.PubMedGoogle Scholar
  56. 56.
    Kleaveland JP, Kussmaul WG, Vinciguerra T, Diters R, Carabello BA. Volume overload hypertrophy in a closed-chest model of mitral regurgitation. Am J Physiol Heart Circ Physiol 1988;254:H1034–41.Google Scholar
  57. 57.
    Tsutsui H, Spinale FG, Nagatsu M, et al. Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994;93:2639–48.PubMedCrossRefGoogle Scholar
  58. 58.
    Spinale FG, Ishihra K, Zile M, et al. Structural basis for changes in left ventricular function and geometry because of chronic mitral regurgitation and after correction of volume overload. J Thorac Cardiovasc Surg 1993;106:1147–57.PubMedGoogle Scholar
  59. 59.
    Dell'Italia LJ. The renin-angiotensin system in mitral regurgitation: a typical example of tissue activation. Curr Cardiol Rep 2002;4:97–105.PubMedCrossRefGoogle Scholar
  60. 60.
    Perry GJ, Chih-Chang W, Hankes GH, et al. Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol 2002;39:1374–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Ishihara K, Zile MR, Tomita M, et al. Left ventricular hypertrophy in a canine model of reversible pressure overload. Cardiovasc Res 1992;26:580–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Alyono D, Anderson RW, Parrish DG, Dai XZ, Bache RJ Alterations of myocardial blood flow associated with experimental canine left ventricular hypertrophy secondary to valvular aortic stenosis. Circ Res 1986;58:47–57.PubMedGoogle Scholar
  64. 64.
    Hsieh CM, Mishkel GJ, Cardoso PF, et al. Production and reversibility of right ventricular hypertrophy and right heart failure in dogs. Ann Thorac Surg 1992;54:104–10.PubMedCrossRefGoogle Scholar
  65. 65.
    Nguyen TN, Chagas AC, Glantz SA. Left ventricular adaptation to gradual renovascular hypertension in dogs. Am J Physiol 1993; 265(1 Pt 2):H22–38.PubMedGoogle Scholar
  66. 66.
    Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic dysfunction. Circulation 2002;105:1387–93.PubMedCrossRefGoogle Scholar
  67. 67.
    Narula J, Zaret BL. Epilogue: development of novel imaging techniques for ultimately superior management of congestive heart failure. J Nucl Cardiol 2002;9(5 Suppl):81S-6S.PubMedCrossRefGoogle Scholar
  68. 68.
    Kraitchman DL, Bluemke DA, Chin BB, Heldman AW, Heldman AW. A minimally invasive method for creating coronary stenosis in a swine model for MRI and SPECT imaging. Invest Radiol 2000;35:445–51.PubMedCrossRefGoogle Scholar
  69. 69.
    Young AA, Orr R, Smaill BH, Dell'Italia LJ. Three-dimensional changes in left and right ventricular geometry in chronic mitral regurgitation. Am J Physiol 1996;271(6 Pt 2):H2689–700.PubMedGoogle Scholar
  70. 70.
    Wu JC, Inubushi M, Sundaresan G, Schelbert HR, Gambhir SS. Positron emission tomography imaging of cardiac reporter gene expression in living rats. Circulation 2002;106:180–3.PubMedCrossRefGoogle Scholar
  71. 71.
    Bremer C, Tung C, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001; 7:743–48.PubMedCrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2003

Authors and Affiliations

  • William M. Yarbrough
    • 1
  • Francis G. Spinale
    • 1
  1. 1.Cardiothoracic Surgery, Room 625, Strom Thurmond Research Building, 770 MUSC ComplexMedical University of South CarolinaCharleston

Personalised recommendations